Indonesia’s mushroom protein firm Meatless Kingdom is set to embark on a business strategy revamp, including international distribution and a focus on flavour enhancement.
Asia’s first mycoprotein technology firm Mycovation believes that its products are the true future of alternative protein, with the firm touting its flavour, nutrition and sustainability credentials.
Thai mushroom-based protein firm More Meat is taking steps towards obtaining clean label recognition while also working on launching a new line of ready-to-cook (RTC) products to later this year.
Colorado-based MycoTechnology – which is building a functional ingredients platform utilizing mycelium, the filament-like roots of mushrooms - has raised $85m in a series E* round (taking its total funding to $200m) that will help it expand its portfolio...
New Zealand start-up Mushroom Material has developed a sustainable mushroom-based material as an alternative to polystyrene styrofoam and cardboard packaging and is targeting the cosmetics sector for its first products.
Australian mushroom-based meat firm Fable Food is making plans for widespread international expansion as well as intensive new product development using the fresh funding obtained from its latest seed round.
Australia-based plant-based firm Fable Foods says a relentless focuses on greater premiumisation and minimal processing for its shiitake mushroom-based products are enabling it to maintain price parity with conventional meat items.
Medicinal fungi ingredients could be among the biggest winners in the new retail landscape of the dietary supplement industry, according to new data published by the American Botanical Council.
Habitual mushroom intake may help to prevent prostate cancer, especially in middle-aged and elderly Japanese men, according to the findings of a new cohort study.
There is growing evidence that certain plant-based nutrients in tea and mushroom may help to delay cognitive decline as we age, and may provide more promising focuses for further research after multiple products touted by the pharma sector ended in failure.